Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Carsten Däweritz remains CFO of Evolva


Evolva Holding SA / Key word(s): Personnel
Carsten Däweritz remains CFO of Evolva

28-Feb-2022 / 07:00 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.


PRESS RELEASE | AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR

Reinach, February 28, 2022 - Evolva (SIX:EVE), a pioneer in the field of natural molecules and industrial biotech, has transformed in recent years from a R&D stage company to a commercial company with an innovative specialty-fermentation platform and a product-based revenue model. The next phase of development will focus on commercializing the company's product portfolio as well as further developing the organization and production network. This offers attractive opportunities for Evolva and its team. In this context, CFO Carsten Däweritz has withdrawn his resignation which was announced on November 30, 2021 and looks forward to playing a key role in the future development of Evolva as a member of the Executive Management.

Stephan Schindler, Chairman of the Audit Committee of Evolva, comments: 'Over the course of the past 12 months, I have experienced Carsten as a highly professional and competent CFO. I look forward to continuing to work closely with him, always focused on value creation.'

Christian Wichert, CEO of Evolva adds: 'I am pleased that we can ensure continuity with Carsten in the important role of CFO. Together with Carsten and the leadership team, we are committed to advance the organization through the commercial scale-up and to bring Evolva to the next level.'

Evolva will present its full-year 2021 results on March 10, 2022 and will hold a conference call for media, analysts and investors at 10.00am CET.

About Evolva
Evolva is a Swiss biotech company focused on the research, development and commercialization of ingredients based on nature. We have leading businesses in Flavors and Fragrances, Health Ingredients and Health Protection. Evolva's employees, half of which are women, are dedicated to make the best products that can contribute to health, wellbeing and sensory enjoyment. Find out more at evolva.com and connect with us on LinkedIn.

For Evolva multimedia content, please visit: evolva.com/multimedia-library.

Disclaimer
This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.

Contact
Thomas Schneckenburger, PhD, CFA
Head of Investor and Corporate Relations
+41 61 485 2003
+41 79 407 9952
[email protected]



End of ad hoc announcement
Language: English
Company: Evolva Holding SA
Duggingerstrasse 23
4153 Reinach
Switzerland
Phone: +41 61 485 20 00
Internet: www.evolva.com
ISIN: CH0021218067
Valor: 2121806
Listed: SIX Swiss Exchange
EQS News ID: 1289319

 
End of Announcement EQS News Service

1289319  28-Feb-2022 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1289319&application_name=news&site_id=sharewise
Like: 0
Share
EQS Group is a leading international provider of regulatory technology in the fields of corporate compliance and investor relations. In working with EQS Group, thousands of companies worldwide inspire trust by fulfilling complex national and international disclosure obligations, minimizing risks and communicating transparently with stakeholders.




Legal notice

Comments